Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.12 (
biotinidase
)
392
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Biotinylation of intact mammalian red blood cells (RBC) was performed either by attachment to the amino groups by means of biotin N-hydrosuccinimide ester (NHS-biotin) or by oxidation of the induced
aldehyde
groups of the RBC membrane by biotin hydrazide. Comparison of these different procedures showed that biotinylation by NHS-biotin provided the highest cell recovery (> 90%), the binding of approximately 1000 biotin molecules/cell (on mouse RBC) and the 24 h survival in circulation was unaffected. In contrast, biotin hydrazide produced cell recovery in the 5-30% range (depending on the extent of oxidation), an undetectable number of molecules of biotin/cell and negligible 24 h survival. Among the NHS derivatives of biotin, further studies were performed on those containing a spacer arm of 2.2 nm (22 A) [sulphosuccinimidyl-6-(biotinamido)-hexanoate]. In vitro this derivative was similar to, or better than, the NHS-biotin in terms of cell recovery and the number of molecules/cell. In vivo this derivative showed a 24 h circulation survival similar to that of NHS-biotin. Unfortunately, biotin bound with such a spacer arm is lost after a few days of RBC circulation, probably due to plasma
biotinidase
. Possible applications of biotinylated RBCs include the in vivo measurement of RBC volume, the RBC survival and the delivery of enzyme and antigens.
...
PMID:Preparation and characterization of biotinylated red blood cells. 781 3